These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

265 related articles for article (PubMed ID: 18443352)

  • 21. Clinical applicability and prognostic significance of molecular response assessed by fluorescent-PCR of immunoglobulin genes in multiple myeloma. Results from a GEM/PETHEMA study.
    Martinez-Lopez J; Fernández-Redondo E; García-Sánz R; Montalbán MA; Martínez-Sánchez P; Pavia B; Mateos MV; Rosiñol L; Martín M; Ayala R; Martínez R; Blanchard MJ; Alegre A; Besalduch J; Bargay J; Hernandez MT; Sarasquete ME; Sanchez-Godoy P; Fernández M; Blade J; San Miguel JF; Lahuerta JJ;
    Br J Haematol; 2013 Dec; 163(5):581-9. PubMed ID: 24117042
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Application of flow cytometry immunophenotyping and multidrug resistance assay in B-cell acute lymphoid leukemia and multiple myeloma.
    Jakab K; Gopcsa L; Adam E; Domjan G; Sarkadi B; Paloczi K
    Neoplasma; 2005; 52(1):36-42. PubMed ID: 15739024
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Biological and prognostic significance of interphase fluorescence in situ hybridization detection of chromosome 13 abnormalities (delta13) in multiple myeloma: an eastern cooperative oncology group study.
    Fonseca R; Harrington D; Oken MM; Dewald GW; Bailey RJ; Van Wier SA; Henderson KJ; Blood EA; Rajkumar SV; Kay NE; Van Ness B; Greipp PR
    Cancer Res; 2002 Feb; 62(3):715-20. PubMed ID: 11830525
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Combinations of cytogenetics and international scoring system can predict poor prognosis in multiple myeloma after high-dose chemotherapy and autologous stem cell transplantation.
    Inamoto Y; Kurahashi S; Imahashi N; Fukushima N; Adachi T; Kinoshita T; Tsushita K; Miyamura K; Naoe T; Sugiura I
    Am J Hematol; 2009 May; 84(5):283-6. PubMed ID: 19338045
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic significance of plasma cell propidium iodide and annexin-V indices and their mutual ratio in multiple myeloma.
    Scudla V; Ordeltova M; Minarik J; Dusek L; Zemanova M; Bacovsky J
    Neoplasma; 2006; 53(3):213-8. PubMed ID: 16652190
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic value of plasma-cell immunophenotype in patients with multiple myeloma.
    Sakalová A; Holománová D; Mikulecký M; Mistrík M; Lipsic T; Steruská M
    Neoplasma; 1993; 40(6):351-4. PubMed ID: 8289966
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Abnormalities of chromosome 1p/q are highly associated with chromosome 13/13q deletions and are an adverse prognostic factor for the outcome of high-dose chemotherapy in patients with multiple myeloma.
    Wu KL; Beverloo B; Lokhorst HM; Segeren CM; van der Holt B; Steijaert MM; Westveer PH; Poddighe PJ; Verhoef GE; Sonneveld P; ;
    Br J Haematol; 2007 Feb; 136(4):615-23. PubMed ID: 17223915
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Absolute lymphocyte count at the time of first relapse predicts survival in patients with diffuse large B-cell lymphoma.
    Porrata LF; Ristow K; Habermann TM; Witzig TE; Inwards DJ; Markovic SN
    Am J Hematol; 2009 Feb; 84(2):93-7. PubMed ID: 19123458
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Review of phenotypic markers used in flow cytometric analysis of MGUS and MM, and applicability of flow cytometry in other plasma cell disorders.
    Raja KR; Kovarova L; Hajek R
    Br J Haematol; 2010 May; 149(3):334-51. PubMed ID: 20201947
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Expression of CD56 and CD19 in Patients with Newly Diagnosed Multiple Myeloma and Their Relationship with Karyotypes and Prognosis].
    Qiu Q; Zhu P; Wang MJ; Lu XZ; Dong YJ; Sun YH; Wang LH; Zhang Y; Bu DF; Wang WS; Liang ZY; Liu W; Qiu ZX; Ou JP; Cen XN
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2016 Aug; 24(4):1071-8. PubMed ID: 27531777
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Epigenetic silencing of the tetraspanin CD9 during disease progression in multiple myeloma cells and correlation with survival.
    De Bruyne E; Bos TJ; Asosingh K; Vande Broek I; Menu E; Van Valckenborgh E; Atadja P; Coiteux V; Leleu X; Thielemans K; Van Camp B; Vanderkerken K; Van Riet I
    Clin Cancer Res; 2008 May; 14(10):2918-26. PubMed ID: 18483358
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrospective analysis of intravascular large B-cell lymphoma treated with rituximab-containing chemotherapy as reported by the IVL study group in Japan.
    Shimada K; Matsue K; Yamamoto K; Murase T; Ichikawa N; Okamoto M; Niitsu N; Kosugi H; Tsukamoto N; Miwa H; Asaoku H; Kikuchi A; Matsumoto M; Saburi Y; Masaki Y; Yamaguchi M; Nakamura S; Naoe T; Kinoshita T
    J Clin Oncol; 2008 Jul; 26(19):3189-95. PubMed ID: 18506023
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Age 40 years and under does not confer superior prognosis in patients with multiple myeloma undergoing upfront autologous stem cell transmplant.
    Cheema PK; Zadeh S; Kukreti V; Reece D; Chen C; Trudel S; Mikhael J
    Biol Blood Marrow Transplant; 2009 Jun; 15(6):686-93. PubMed ID: 19450753
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Circulating levels and clinical significance of soluble CD86 in myeloma patients.
    Hock BD; Drayson M; Patton WN; Taylor K; Kerr L; McKenzie JL
    Br J Haematol; 2006 Apr; 133(2):165-72. PubMed ID: 16611307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Flow cytometric immunophenotyping and minimal residual disease analysis in multiple myeloma.
    Gupta R; Bhaskar A; Kumar L; Sharma A; Jain P
    Am J Clin Pathol; 2009 Nov; 132(5):728-32. PubMed ID: 19846814
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
    Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
    J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lack of CD56 expression on myeloma cells is not a marker for poor prognosis in patients treated by high-dose chemotherapy and is associated with translocation t(11;14).
    Hundemer M; Klein U; Hose D; Raab MS; Cremer FW; Jauch A; Benner A; Heiss C; Moos M; Ho AD; Goldschmidt H
    Bone Marrow Transplant; 2007 Dec; 40(11):1033-7. PubMed ID: 17891186
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Two cases of plasma cell leukemia with atypical immunophenotype.
    Buda G; Carulli G; Orciuolo E; Cannizzo E; Zucca A; Azzarà A; Rossi A; Galimberti S; Cecconi N; Petrini M
    Acta Haematol; 2007; 118(1):27-9. PubMed ID: 17429194
    [No Abstract]   [Full Text] [Related]  

  • 39. Impact of previous tracheotomy as a prognostic factor in patients with locally advanced squamous cell carcinoma of the larynx submitted to concomitant chemotherapy and radiation.
    Herchenhorn D; Dias FL; Ferreira CG; Araújo CM; Lima RA; Small IA; Kligerman J
    ORL J Otorhinolaryngol Relat Spec; 2008; 70(6):381-8. PubMed ID: 18984974
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chromosomal translocations t(4;14), t(11;14) and proliferation rate stratify patients with mature plasma cell myelomas into groups with different survival probabilities: a molecular epidemiologic study on tissue microarrays.
    Tinguely M; Jenni B; Reineke T; Korol D; Kofler A; Rousson V; Dommann-Scherrer C; Maurer R; Moch H; Probst-Hensch NM
    Am J Surg Pathol; 2007 May; 31(5):690-6. PubMed ID: 17460451
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.